INSERM (Institut national de la santé et de la recherche médicale) is the only public research organization in France entirely dedicated to human health. Its objective is to promote the health of all by advancing knowledge about life and disease, treatment innovation, and public health research.
Since its foundation in 1964, INSERM has played a part in many key medical advances. The Institute is distinguished by both the scientific excellence of its staff, and by its ability to provide benchtop to bedside translational research.
INSERM is the leading European academic biomedical research institution, and with nearly 12,000 publications a year; is second in the world only to the National Institutes of Health (NIH).
Hana Raslova, Research Director (DR2 INSERM) since 2015, is on the head of the Team “From hematopoietic stem cell to megakaryocyte” of the Unit INSERM UMR 1170 localized at Gustave Roussy in Villejuif, France, which is the biggest European Centre dedicated to cancer treatment. The goal of the team is to understand the mechanism of decrease in blood platelets in different disorders to permit new therapeutic approaches. The team comprises together 33 members, some of them will directly participate to the proposal.
